Fat Loss Stack (GLP-1 + CJC-1295/Ipamorelin)
A research overview of the combination of GLP-1 receptor agonists with CJC-1295 and Ipamorelin, bridging two distinct metabolic axes. GLP-1 agents act on appetite regulation and glucose metabolism. CJC-1295 and Ipamorelin act on the GH axis to support lean mass preservation and metabolic rate. This stack bridges the weight loss cluster and the hormone optimization cluster.
Science simplified
The Fat Loss Stack combines a GLP-1 receptor agonist with CJC-1295 and Ipamorelin, pairing the appetite suppression and metabolic effects of GLP-1 compounds with the growth hormone axis support of two selective GH secretagogues. The GLP-1 agent addresses appetite and glucose regulation while CJC-1295 and Ipamorelin support GH-mediated fat metabolism and body composition. The GLP-1 component includes FDA-approved options. The GH secretagogue components are research peptides only.
Best researched for
Fat metabolism · appetite regulation · body composition
Evidence stage
GLP-1 FDA Approved established · GH peptides Animal Studies through Human Trials research only
Approval status
GLP-1 FDA-approved · GH peptides research use only
FDA Approved / Human Trials / Animal Studies
Compound Evidence Levels
None
Combination Trial Data
3
Compounds
Dual Axis
Metabolic Approach
PSI Verdict
Supported by evidence
Fat loss peptide stacks typically combine GH secretagogues with lipolytic compounds to address fat metabolism through multiple pathways simultaneously. The individual mechanisms of the compounds in this stack are independently characterized in preclinical research, and the multi-pathway rationale reflects genuine mechanistic thinking about adipose tissue metabolism.
Not yet established
Combination evidence for any fat loss peptide stack does not exist in controlled human trials. The additive or synergistic fat loss effects assumed by multi-compound protocols are mechanistically plausible but entirely unvalidated. No fat loss peptide stack has demonstrated superiority over single-compound approaches in human research.
Confidence level
The fat loss stack category has the largest gap between popular use and clinical evidence of any stack class in this library. The individual compounds have preclinical support. The combination protocols are constructed from mechanistic reasoning with no combination trial data to validate them.
Stack Rationale
GLP-1 agents (semaglutide, tirzepatide): Reduce appetite, slow gastric emptying, and improve insulin sensitivity, producing significant fat mass reduction. These are FDA-approved compounds with Phase III RCT data demonstrating substantial weight loss efficacy.
CJC-1295: Stimulates GH release via GHRH receptors, producing downstream IGF-1 elevation. A GHRH analog with Phase II human pharmacokinetic data confirming sustained GH and IGF-1 elevation.
Ipamorelin: Amplifies GH pulses via ghrelin receptors (GHS-R1a). A highly selective GH secretagogue that stimulates GH release without elevating cortisol or prolactin.
Theoretical rationale: GLP-1 drives fat loss while GH axis stimulation supports lean mass preservation during caloric deficit, addressing the muscle loss concern associated with aggressive GLP-1-driven weight loss. This rationale is mechanistic and has not been tested in combination trials.
Important limitation: No combination trials exist. The evidence levels are not equivalent across compounds in this stack, GLP-1 agents are FDA Approved with FDA approval, CJC-1295 is Human Trials with Phase II human data, and Ipamorelin is Animal Studies with limited human data. The stack rationale is derived entirely from individual compound profiles.
In everyday terms: The Fat Loss Stack works on two separate fat reduction pathways simultaneously. The GLP-1 agent suppresses appetite and slows digestion, reducing how much you eat. CJC-1295 and Ipamorelin stimulate growth hormone release which promotes fat burning through a completely separate metabolic pathway. One addresses intake, the other addresses metabolism.
Compound Profiles
FDA-approved GLP-1 receptor agonist with Phase III RCT data demonstrating significant weight loss. Acts on appetite regulation, gastric emptying, and glucose metabolism. The most well-characterized compound in this stack with the strongest evidence base.
A GHRH analog with Phase II human pharmacokinetic data confirming sustained GH and IGF-1 elevation. Stimulates pituitary GH release via GHRH receptors. Research must distinguish between DAC (long-acting) and No-DAC (Mod GRF 1-29, short-acting, pulsatile) formulations, they are pharmacokinetically distinct.
A highly selective GH secretagogue that stimulates GH release via ghrelin receptors (GHS-R1a) without elevating cortisol or prolactin. Limited human clinical data. Valued for its selectivity compared to other ghrelin mimetics.
Mechanistic Comparison
| Dimension | GLP-1 Agent | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Primary target | GLP-1R | GHRH-R | GHS-R1a |
| Primary effect | Appetite suppression + glucose metabolism | GH elevation via GHRH | GH pulse amplification |
| Body composition | Fat mass reduction | Lean mass support via IGF-1 | Lean mass support via GH |
| Evidence level | FDA Approved | Human Trials | Animal Studies |
| FDA status | Approved | Research peptide | Research peptide |
Evidence Summary
What people commonly research this for
- , Fat loss combining GLP-1 appetite suppression with GH-mediated lipolysis
- , Body composition improvement research
- , Metabolic optimization protocols
GLP-1 component is FDA-approved and requires medical supervision. GH peptide components are research use only. No combination trials exist.
Individual Compound Evidence
GLP-1 agents have Phase III RCT data and FDA approval for weight loss, they represent FDA Approved (Strong Evidence). CJC-1295 has Phase II human pharmacokinetic data confirming GH and IGF-1 elevation, rated Human Trials (Moderate Evidence). Ipamorelin has limited human data, rated Animal Studies (Preliminary Evidence). The evidence levels are not equivalent across this stack; GLP-1 agents are far better characterized than either GH secretagogue.
Combination Evidence
No controlled studies have evaluated GLP-1 agents in combination with CJC-1295 or Ipamorelin. The stack rationale addresses a theoretical gap in GLP-1 protocols (lean mass preservation during aggressive caloric deficit) but this has not been tested in combination trials. Whether GH axis stimulation meaningfully attenuates GLP-1-associated lean mass loss is unknown.
Safety Considerations
Individual Safety Profiles
GLP-1 agents have well-characterized safety profiles from large clinical trials, common adverse effects include nausea and GI effects, with rare pancreatitis risk. CJC-1295 has mild injection site reactions reported in Phase II data. Ipamorelin demonstrates no cortisol or prolactin elevation, distinguishing it from less selective ghrelin mimetics.
Combination Safety. Unknown
No safety data exists for combined use of GLP-1 agents with GH secretagogues. Notably, GLP-1 agents and GH secretagogues have opposing effects on insulin sensitivity, GLP-1 improves insulin sensitivity while GH can induce insulin resistance. This metabolic interaction requires careful consideration and has not been characterized in combination studies.
Research Context
Researchers interested in the individual mechanisms behind this stack can review the full compound profiles for Semaglutide, CJC-1295, and Ipamorelin.
For a broader overview of peptides studied for weight management, see the peptides for weight loss roundup.
For peptides studied for GH axis and endocrine optimization, see the peptides for hormone optimization roundup.
This stack is reviewed in the context of the broader weight loss research literature on this site.
The CJC-1295 and Ipamorelin pairing is covered in detail on the CJC-1295 + Ipamorelin (No-DAC) stack page.
Medical Disclaimer
This page is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research compounds not approved for human therapeutic use as a stack. Always consult a qualified healthcare professional. PSI aggregates publicly available research and does not conduct original clinical trials.